David R. Driscoll

2.1k total citations · 1 hit paper
21 papers, 1.5k citations indexed

About

David R. Driscoll is a scholar working on Materials Chemistry, Oncology and Molecular Biology. According to data from OpenAlex, David R. Driscoll has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Materials Chemistry, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in David R. Driscoll's work include Advancements in Solid Oxide Fuel Cells (6 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Electronic and Structural Properties of Oxides (3 papers). David R. Driscoll is often cited by papers focused on Advancements in Solid Oxide Fuel Cells (6 papers), Pancreatic and Hepatic Oncology Research (4 papers) and Electronic and Structural Properties of Oxides (3 papers). David R. Driscoll collaborates with scholars based in United States, Japan and United Kingdom. David R. Driscoll's co-authors include Daniel A. Haber, Brian W. Brannigan, Daphne W. Bell, Patricia L. Harris, Eunice L. Kwak, Ross A. Okimoto, Kurt J. Isselbacher, Allan Wissner, Nadia Godin-Heymann and Sreenath V. Sharma and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Gastroenterology.

In The Last Decade

David R. Driscoll

21 papers receiving 1.5k citations

Hit Papers

Irreversible inhibitors of the EGF receptor may circumven... 2005 2026 2012 2019 2005 250 500 750

Peers

David R. Driscoll
Comparison fields: 5 of 76
  • Molecular Biology 850
  • Oncology 779
  • Pulmonary and Respiratory Medicine 710
  • Cancer Research 214
  • Organic Chemistry 118
Replace Xianghua Wu with:
Xianghua Wu China
Takuya Kato Japan
Jacson Shen United States
Jian H. Song United States
Michiro Susa Japan
Yufa Li China
Shoichiro Ohtani Japan
Becker Hewes United States
Rebecca G. Bagley United States
Shinji Kohsaka Japan
Xianghua Wu China View profile →
Citations per field, relative to David R. Driscoll
David R. Driscoll · 1×
Citations per year, relative to David R. Driscoll
David R. Driscoll · 1×

Countries citing papers authored by David R. Driscoll

Since Specialization
Citations

This map shows the geographic impact of David R. Driscoll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Driscoll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Driscoll more than expected).

Fields of papers citing papers by David R. Driscoll

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Driscoll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Driscoll. The network helps show where David R. Driscoll may publish in the future.

Co-authorship network of co-authors of David R. Driscoll

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Driscoll. A scholar is included among the top collaborators of David R. Driscoll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Driscoll. David R. Driscoll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1 7
2 1
3 4
4 4
5 23
6 58
7 14
8 50
9 5
10 29
11 38
12 4
13 96
14 11
15
Novel human pathological mutations. Gene symbol: PTEN. Disease: PTEN Hamartoma Tumour Syndrome.
4
16 225
17 133
18
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib breakdown →
774
19 5
20 3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026